

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

VOLUNTARY ANNOUNCEMENT
PROGRESS UPDATE ON PURCHASES OF H SHARES
PURSUANT TO THE SHARE INCENTIVE SCHEME

This announcement is made by Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Company about the latest progress of the Company’s share incentive scheme (the “**Share Incentive Scheme**”).

Reference is made to (i) the announcement of the Company dated 29 April 2026 in relation to the proposed adoption of the Share Incentive Scheme; (ii) the circular of the Company dated 30 April 2026 (the “**Circular**”); and (iii) resolution 16 passed by way of a special resolution at the annual general meeting of the Company held on 27 May 2026 (the “**AGM**”), pursuant to which the formulation of the implementation plan for the Share Incentive Scheme was considered and approved, and the board of directors of the Company (the “**Board**”) and/or its authorized persons were authorized to handle all matters relating to the Share Incentive Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As of 16 October 2026, the trustee appointed for the purpose of the Share Incentive Scheme has purchased on the secondary market of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) an aggregate of 394,900 H Shares of the Company (the “**Share Purchases**”), representing approximately 0.502% of the total number of issued shares of the Company as at the date of this announcement. The H Shares purchased by the trustee will be held in trust for the eligible participants under the Share Incentive Scheme and will be used for future grants in accordance with the terms of the Share Incentive Scheme.

Any further share purchases under the Share Incentive Scheme will be subject to market conditions and will be determined at the sole discretion of the Board and/or its authorized persons, and there is no assurance as to the timing, number or price of any further share purchases. The Company will make further announcements on the progress of the Share Incentive Scheme as and when appropriate in accordance with the Rules Governing the Listing of Securities on the Stock Exchange and the terms of the Share Incentive Scheme.

Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any Shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 20 October 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming, Mr. Li Junqing and Mr. Chen Tingze as executive Directors; (ii) Mr. Xu Dong as non-executive Director; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.